IIRC ACW's XanaMEM selectively prevents cortisol uptake in the brain. Elevated cortisol is a feature of neurological disease and lowered cognitive functioning.
In previous trials XanaMEM has resulted in higher cognitive functioning using a battery of psychometric tests, both in those with some underlying neurological condition and those without, i.e. it seems to be an effective nootropic in general.
Currently trial is in a population of people suffering with MDD (Major Depressive Disorder) which is associated with lowered cognitive functioning. Given the summary of evidence above, it seems reasonable to speculate that the study will meet its endpoints (IIRC includes the same tests as above). It also seems reasonable to think that better general cognitive functioning may result in some sense of well-being, i.e. lower subjective scores of depression.
Trial results are due "early Q3". The SP seems to behave fairly predictably with trial results on the horizon... Maybe something similar to what BIT did in anticipation of results (hopefully).
ACW is running a longer trial in Alzheimers with results due Q2 2025. That's the big one... Less certain about how the SP will behave leading up to that trial, and how results in the MDD trial will nuance expectations about its efficacy in Alzheimers.
